In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...
As with PTSD, people develop acute stress disorder after exposure to traumatic events. The key difference in the diagnostic ...
This new generic medicine is designed to be a simple, once-daily treatment for children as young as three months old who ...
Wendy Watson takes over Kaiser Foundation Health Plan and Hospitals of the Northwest, and Corwin N. Harper becomes president ...
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and ...
Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
Human Metapneumovirus (HMPV) is a respiratory virus that may not be on most folk’s radars, but it’s more common than you ...
The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...
The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback